Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 158, Issue -, Pages 302-310Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.09.014
Keywords
P2Y(1) receptor antagonist; 2-(phenoxyaryl)-3-urea derivatives; Anti-Platelet
Categories
Funding
- National Natural Science Foundation of China [81620108027, 21632008, 21672231, 21472209]
- Major Project of Chinese National Programs for Fundamental Research and Development [2015CB910304]
Ask authors/readers for more resources
A novel series of 2-(phenoxyaryl)-3-urea derivatives were designed, synthesized, and biologically evaluated for their anti-thrombotic activity. Most of compounds exhibited good inhibition against P2Y(1) receptor. Among them, three compounds 11, 12, and 13 demonstrated good P2Y(1) receptor antagonistic potency in vitro (IC50 = 0.62 mu M, 0.82 mu M, and 0.21 mu M, respectively). In antiplatelet aggregation study, four compounds 2, 3, 9, and 13 showed good antiplatelet activity. The possible binding modes of compounds with P2Y(1) receptor were also explored by molecular docking simulation. The docking studies demonstrated that compound 13 interacted well with Phe119 through hydrophobic interaction and modestly improved the P2Y(1) receptor antagonistic activity, making it justifiable for further investigation. (C) 2018 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available